On the Binding of Monoamine Oxidase Inhibitors to Some Sites Distinct from the MAO Active Site, and Effects Thereby Elicited

NeuroToxicology

Volumn 25, Issue 1-2, 2004, Pages 251-266

  Holt, Andrew ^a,b   Berry, Mark D ^a   Boulton, Alan A ^a  

^a ALviva Biopharmaceuticals Inc   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Biogenic amine receptors; Diamine oxidase (DAO); Imidazoline binding sites; Monoamine oxidase (MAO); Neuroprotection; Plasma amine oxidase (PAO); Pyridoxal phosphate (PLP); Semicarbazide sensitive amine oxidase (SSAO); Trace amine receptors

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; AMINE OXIDASE (COPPER CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BROFAROMINE; CLORGYLINE; CYTOCHROME P450; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; HYDRAZINE DERIVATIVE; IMIDAZOLINE RECEPTOR; IPRONIAZID; LAZABEMIDE; MOCLOBEMIDE; MOFEGILINE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; N [2 (2 CHLOROPHENOXY)ETHYL]CYCLOPROPYLAMINE; PARGYLINE; PHENELZINE; POLYAMINE OXIDASE; PROTEIN LYSINE 6 OXIDASE; PUTRESCINE; PYRIDOXAL 5 PHOSPHATE; SELEGILINE; SIGMA OPIATE RECEPTOR; TRANYLCYPROMINE; TYRAMINE; UNINDEXED DRUG;

4 AMINOBUTYRIC ACID BRAIN LEVEL; AMINE TRANSPORT; ANGINA PECTORIS; ATTENTION DEFICIT DISORDER; BINDING AFFINITY; BINDING SITE; BIPOLAR DEPRESSION; BLOOD VESSEL INJURY; BRAIN SYNAPTOSOME; DEAMINATION; DOPAMINE UPTAKE; DRUG POTENCY; DRUG PROTEIN BINDING; EATING DISORDER; ENZYME ACTIVITY; ENZYME BINDING; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE; FACE PAIN; HUMAN; HYDROLYSIS KINETICS; HYDROPHOBICITY; HYPERTENSIVE CRISIS; INFLAMMATION; LIGAND BINDING; LYMPHOCYTE; MIGRAINE; NEURODERMATITIS; NEUROPROTECTION; NONHUMAN; ORTHOSTATIC HYPOTENSION; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS; THOUGHT DISORDER;

GYMNOMYZA SAMOENSIS;

EID: 0346785246     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-813X(03)00104-9     Document Type: Article

References (118)

1. Alemany R, Olmos G, Garcia-Sevilla JA. The effects of phenelzine and other monoamine oxidase inhibitor anti-depressants on brain and liver I2 imidazoline-preferring receptors. Br J Pharmacol 1995;114:837-45.
2. 3H]dopamine: a reflection of antidepressant potency. Biochem Pharmacol 1982;31:2195-7.
3. Baker GB, Urichuk LJ, McKenna KF, Kennedy SH. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 1999;19:411-26.
4. Bal-Price A, Brown GC. Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 2001;21:6480-91.
5. Bergeron R, Debonnel G, de Montigny C. Modification of the N-methyl-D-aspartate response by antidepressant sigma receptor ligands. Eur J Pharmacol 1993;240:319-23.
6. Bergeron R, de Montigny C, Debonnel G. Biphasic effects of sigma ligands on the neuronal response to N-methyl-D-aspartate. Naunyn-Schmiedeberg's Arch Pharmacol 1995;351:252-60.
7. Berry MD. R-2HMP: an orally active agent combining independent antiapoptotic and MAO-B-inhibitory activities. CNS Drug Rev 1999;5:105-24.
8. Best CH. The disappearance of histamine from autolysing lung tissue. J Physiol 1929;67:256-63.
9. Best CH, McHenry EW. The inactivation of histamine. J Physiol 1930;70:349-72.
10. Binda C, Newton-Vinson P, Hubálek F, Edmondson DE, Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nature Struct Biol 2002;9:22-6.
11. Blaschko H, Duthie R. Substrate specificity of amine oxidases. Biochem J 1945;39:478-81.
12. Blaschko H, Richter D, Schlossmann H. The inactivation of adrenaline. J Physiol 1937a;90:1-17.
13. Blaschko H, Richter D, Schlossmann H. The oxidation of adrenaline and other amines. Biochem J 1937b;31:2187-96.
14. Blaschko H, Friedman PJ, Hawes R, Nilsson K. The amine oxidases of mammalian plasma. J Physiol 1959;145:384-404.
15. Borowgky B, Adham N, Jones KA, Raddatz R, Artymyshyn R, Ogozalek KL et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA 2001;98:8966-71.
16. Boudikova-Gerard B, Scott MC, Weinshilboum R. Histamine N-methyltransferase: inhibition by monoamine oxidase inhibitors. Agents Actions 1993;40:1-10.
17. Boulton AA. Some aspects of basic psychopharmacology: the trace amines. Prog Neuropsychopharmacol Biol Psychiatr 1982;6:563-70.
18. Bourgain RH, Andries R, Decuyper K, De Clerck F. Dual inhibition of thromboxane A2 synthesis and thromboxane A2/ prostaglandin endoperoxide receptors by ridogrel: anti-thrombotic effect in vivo in rat mesenteric arteries. J Lipid Mediat 1991;3:3-11.
19. Bousquet P, Feldman J, Schwartz J. Central cardiovascular effects of α-adrenergic drugs: differences between catecholamines and imidazolines. J Pharmacol Exp Ther 1984;230:232-6.
20. Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI et al. Amphetamine, 3,4-methylene-dioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists for a rat trace amine receptor. Mol Pharmacol 2001;60:1181-8.
21. Carrington MJ, Bird TA, Levene CI. The inhibition of lysyl oxidase in vivo by isoniazid and its reversal by pyridoxal. Effect on collagen cross-linking in the chick embryo. Biochem J 1984;221:837-43.
22. 14C, an irreversible inhibitor of monoamine oxidase I. Studies in vitro. Biochem Pharmacol 1969;18:1011-20.
23. Cohen G. Monoamine oxidase and oxidative stress at dopaminergic synapses. J Neural Transm 1990;32(Suppl):229-38.
24. Culver KE, Szechtman H. Monoamine oxidase inhibitor sensitive site implicated in sensitization to quinpirole. Eur J Pharmacol 1997;339:109-11.
25. Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, Jarreau FX. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther 1996;277:253-64.
26. Czerwiec E, De Backer JP, Flamez A, Vauquelin G. Identification and characterisation of imidazoline-binding sites from calf striatum. Eur J Pharmacol 1996;315:99-109.
27. Davis BA, Boulton AA. The trace amines and their acidic metabolites in depression-an overview. Prog Neuropsychopharmacol Biol Psychiatr 1994;18:17-45.
28. DeMaster EG, Stevens JM. Acute effects of the aldehyde dehydrogenase inhibitors, disulfiram, pargyline and cyanamide, on circulating ketone body levels in the rat. Biochem Pharmacol 1988;37:229-34.
29. Dove JE, Smith AJ, Kuchar J, Brown DE, Dooley DM, Klinman JP. Identification of the quinone cofactor in a lysyl oxidase from Pichia pastoris. FEBS Lett 1996;398:231-4.
30. Draper AJ, Madan A, Parkinson A. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 1997;341:47-61.
31. Dyck LE. Effect of decarboxylase inhibitors on brain p-tyrosine levels. Biochem Pharmacol 1987;36:1373-6.
32. Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG et al. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci 1998;19:381-90.
33. 3H]-idazoxan binding sites. Br J Pharmacol 1996;118:2029-36.
34. 3 receptors in rat nodose ganglion neurones. Br J Pharmacol 1994;112:741-4.
35. Fang J, Yu PH. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 1994;33:763-8.
36. Ferry G, Loynel A, Kucharczyk N, Bertin S, Rodriguez M, Delagrange P et al. Substrate specificity and inhibition studies of human serotonin N-acetyltransferase. J Biol Chem 2000;275:8794-805.
37. Finberg JPM, Tenne M. Relationship between tyramine potentiation and selective inhibition of monoamine oxidase types A and B in the rat vas deferens. Br J Pharmacol 1982;77:13-21.
38. Fowler CJ, Mantle TJ, Tipton KF. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, L-deprenyl and pargyline. Biochem Pharmacol 1982;31:3555-61.
39. 1B) receptors. Eur J Pharmacol 1990;179:173-6.
40. Geha RM, Rebrin I, Chen K, Shih JC. Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid. J Biol Chem 2001;276:9877-82.
41. Hare MLC. Tyramine oxidase. I. A new enzyme system in liver. Biochem J 1928;22:968-79.
42. Hertz L, Richardson JS. Acute and chronic effects of antidepressant drugs on beta-adrenergic function in astrocytes in primary cultures: an indication of glial involvement in affective disorders. J Neurosci Res 1983;9:173-82.
43. Hidaka H, Inagaki M, Nishikawa M, Tanaka T. Selective inhibitors of calmodulin-dependent phosphodiesterase and other enzymes. Meth Enzymol 1988;159:652-60.
44. Holt A, Baker GB. Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. Prog Brain Res 1995:106:187-97.
45. Holt A, Sharman DF, Baker GB, Palcic MM. A continuous spectrophotometric assay for monoamine oxidase and related enzymes in tissue homogenates. Anal Biochem 1997;244:384-92.
46. Holt A, Alton G, Scaman CH, Loppnow GR, Szpacenko A, Svendsen I et al. Identification of the quinone cofactor in mammalian semicarbazide-sensitive amine oxidase. Biochemistry 1998;37:4946-57.
47. 1receptor density in rat whole brain. Ann NY Acad Sci 2003, accepted.
48. 3H]rilmenidine binding sites in rat brain. J Auton Nerv Syst 1998;72:129-36.
49. Hsu LL. Pineal aryl acylamidase: effects of melatonin, serotonin-related compounds, beta-carbolines, Ro4-4062 and anti-depressants. Res Commun Chem Pathol Pharmacol 1984;43:223-34.
50. 2 binding sites. Ann N Y Acad Sci 1999;881:212-6.
51. Ishitani R, Sunaga K, Hirano A, Saunders P, Katsube N, Chuang D-M. Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem 1996a;66:928-35.
52. Ishitani R, Kimura M, Sunaga K, Hirano A, Katsube N, Tanaka M et al. An antisense oligodeoxynucleotide to glyceraldehyde-3-phosphate dehydrogenase blocks age-induced apoptosis of mature cerebrocortical neurons in culture. J Pharmacol Exp Ther 1996b;278:447-54.
53. Itzhak Y, Stein I, Zhang SH, Kassim CO, Cristante D. Binding of sigma ligands to C57bl/6 mouse brain membranes: effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of sigma receptor subtypes. J Pharmacol Exp Ther 1991;257:141-8.
54. Iyer RK, Kim HK, Tsoa RW, Grody WW, Cederbaum SD. Cloning and characterization of human agmatinase. Mol Genet Metab 2002;75:209-18.
55. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968;17:1285-97.
56. Kakkar R, Raju RV, Rajput AH, Sharma RK. Inhibition of bovine brain calmodulin-dependent cyclic nucleotide phosphodiesterase isozymes by deprenyl. Life Sci 1996;59:337-41.
57. Kennedy SH, Holt A, Baker GB. Monoamine oxidase inhibitors. In: Sadock BJ, Sadock VA., editors. Kaplan and Sadock's comprehensive textbook of psychiatry. 8th ed. Baltimore (MD): Lippincott, Williams & Wilkins; 2004.
58. Kenney WC, Nagy J, Salach JI, Singer TP. Structure of the covalent phenylhydrazine adduct with monoamine oxidase. In: Singer TP, Von Korff RW, Murphy DL, editors. Monoamine oxidase: structure, function, and altered functions. New York: Academic Press; 1979. p. 25-37.
59. Knoll J. R-(-)-Deprenyl (Selegiline, Movergan®) facilitates the activity of the nigrostriatal dopaminergic neuron. J Neural Transm 1987;25(Suppl):45-66.
60. 450. Electronic requirements of the transition state in the turnover of phenylacetylenes. J Biol Chem 1987;262:9793-802.
61. Kragten E, Lalande I, Zimmermann K, Roggo S, Schindler P, Müller D et al. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J Biol Chem 1998;273:5821-8.
62. Kwan S-W, Lewis DA, Zhou BP, Abell CW. Characterization of a dinucleotide-binding site in monoamine oxidase B by site-directed mutagenesis. Arch Biochem Biophys 1995;316:385-91.
63. Lai JCK, Leung TKC, Guest JF, Lim L, Davison AN. The monoamine oxidase inhibitors clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline and serotonin by rat brain synaptosomal preparations. Biochem Pharmacol 1980;29:2763-7.
64. Lamensdorf I, Porat S, Simantov R, Finberg JP. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Br J Pharmacol 1999;126:997-1002.
65. Langford SD, Trent MB, Balakumaran A, Boor PJ. Developmental vasculotoxicity associated with inhibition of semicarbazide-sensitive amine oxidase. Toxicol Appl Pharmacol 1999;155:237-44.
66. 3H]quinpirole binding by monoamine oxidase inhibitors. Life Sci 2002;71:2691-700.
67. 3H]quinpirole binding in rat striatal membranes. Eur J Pharmacol 1993;246:171-8.
68. 3H]quinpirole binding in brain by monoamine oxidase inhibitors: evidence for a potential novel binding site. J Pharmacol Exp Ther 1996;278:145-53.
69. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ. Agmatine: an endogenous clonidine-displacing substance in the brain. Science 1994;263:966-9.
70. Lightcap ES, Silverman RB. Slow-binding inhibition of gamma-aminobutyric acid aminotransferase by hydrazine analogues. J Med Chem 1996;39:686-94.
71. Lyles GA. The interaction of semicarbazide-sensitive amine oxidase with MAO inhibitors. In: Tipton KF, Dostert P, Strolin Benedetti M., editors. Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. London: Academic Press; 1984. p. 547-56.
72. Lyles GA. Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects. Int J Biochem Cell Biol 1996;28:259-74.
73. Malmberg-Aiello P, Ipponi A, Bartolini A, Schunack W. Antiamnesic effects of metoprine and of selective histamine H(1) receptor agonists in a modified mouse passive avoidance test. Neurosci Lett 2000;288:1-4.
74. McKenna KF, McManus DJ, Baker GB, Coutts RT. Chronic administration of the antidepressant phenelzine and its N-acetyl analogue: effects on GABAergic function. J Neural Transm 1994;41 (Suppl):115-22.
75. Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 2002;82:1376-87.
76. Miller JR, Edmondson DE. Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A. Biochemistry 1999;38:13670-83.
77. Möller AD, Grände P-O. Role of prostacyclin and nitric oxide in regulation of basal microvascular hydraulic permeability in cat skeletal muscle. J Vasc Res 1999;36:245-52.
78. Morin N, Lizcano J-M, Fontana E, Marti L, Smih F, Rouet P et al. Semicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes. J Pharmacol Exp Ther 2001;297:563-72.
79. Mure M, Mills SA, Klinman JP. Catalytic mechanism of the DOPA quinone containing copper amine oxidases. Biochemistry 2002;41:9269-78.
80. 1-imidazoline receptors. Br J Pharmacol 2000;129:1057-9.
81. Nagaya Y, Kutsukake M, Chigusa SI, Komatsu A. A trace amine, tyramine, functions as a neuromodulator in Drosophila melanogaster. Neurosci Lett 2002;329:324-8.
82. Novotny WF, Chassande O, Baker M, Lazdunski M, Barbry P. Diamine oxidase is the amiloride binding protein and is inhibited by amiloride analogues. J Biol Chem 1994;269:9921-5.
83. Paterson IA, Juorio AV, Boulton AA. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system? J Neurochem 1990;55:1827-37.
84. 2-binding sites in rabbit brain membranes. Br J Pharmacol 1999;127(Suppl):57.
85. Pugh CEM, Quastel JH. Oxidation of aliphatic amines by brain and other tissues. Biochem J 1937a;31:286-91.
86. Pugh CEM, Quastel JH. Oxidation of amines by animal tissues. Biochem J 1937b;31:2306-21.
87. Raddatz R, Savic SL, Bakthavachalam V, Lesnick J, Jasper JR, McGrath CR et al. Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme. J Pharmacol Exp Ther 2000;292:1135-45.
88. Regunathan S, Reis DJ. Characterization of arginine decarboxylase in rat brain and liver: distinction from ornithine decarboxylase. J Neurochem 2000;74:2201-8.
89. 2-imidazoline-binding proteins using monoamine oxidase-deficient mouse models. Mol Pharmacol 2000;58:1085-90.
90. Roig MG, Bello F, Burguillo FJ, Cachaza JM, Kennedy JF. In vitro interaction between psychotropic drugs and alcohol dehydrogenase activity. J Pharm Sci 1991;80:267-70.
91. Salmi M, Yegutkin GG, Lehvonen R, Koskinen K, Salminen T, Jalkanen S. A cell surface amine oxidase directly controls lymphocyte migration. Immunity 2001;14:265-76.
92. Salvemini D, Wang ZQ, Wyatt PS, Bourdon DM, Marino MH, Manning PT et al. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 1996;118:829-38.
93. Schmiedeberg O. Über das Verhhältniss des Ammoniaks und der primären Monoaminbasen zur Harnstoffbildung im Thierkörper. Naunyn-Schmiedeberg's Arch Pharmacol 1878;8:1-14.
94. 4502B1 by the monoamine oxidase inhibitors R-(-)-deprenyl and clorgyline. Drug Metab Dispos 1996;24:669-75.
95. Shirota FN, DeMaster EG, Elberling JA, Nagasawa HT. Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo. J Med Chem 1980;23:669-73.
96. Sourkes TL, Missala K. Action of inhibitors on monoamine and diamine metabolism in the rat. Can J Biochem 1977;55:56-9.
97. Strolin Benedetti M, Allievi C, Cocchiara G, Pevarello P, Dostert P. Involvement of FAD-dependent polyamine oxidase in the metabolism of milacemide in the rat. Xenobiotica 1992;22:191-7.
98. Tanay VA, Parent MB, Wong JT, Paslawski T, Martin IL, Baker GB. Effects of the antidepressant/antipanic drug phenelzine on alanine and alanine transaminase in rat brain. Cell Mol Neurobiol 2001;21:325-39.
99. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 1991;30:666-72.
100. Tekes K, Tóthfalusi A, Gaál J, Magyar K. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain. Pol J Pharmacol Pharm 1988;40:653-8.
101. 2-imidazoline binding sites on monoamine oxidases. J Biol Chem 1995;270:9856-61.
102. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989;245:519-22.
103. Todd KG, Baker GB. GABA-elevating effects of the antidepressant/ antipanic drug phenelzine in brain: effects of pretreatment with tranylcypromine, (-)-deprenyl and clorgyline. J Affective Disorders 1995;35:125-9.
104. Urichuk LJ, Allison K, Holt A, Greenshaw AJ, Baker GB. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration. J Affective Disorders 2000;58:135-44.
105. Waldmeier PC. On the reversibility of reversible MAO inhibitors. Naunyn-Schmiedeberg's Arch Pharmacol 1985;329:305-10.
106. Waldmeier PC. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine. Prog Neuropsychopharmacol Biol Psychiatr 1993;17:183-98.
107. Waldmeier PC, Baumann PA. Effects of CGP 11305A, a new reversible and selective inhibitor of MAO-A, on biogenic amine levels and metabolism in the rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 1983;324:20-6.
108. Wang SX, Mure M, Medzihradszky KF, Burlingame AL, Brown DE, Dooley DM et al. A crosslinked cofactor in lysyl oxidase: redox function for amino acid side chains. Science 1996;273:1078-84.
109. Whitlock BB, Liu Y, Chang S, Saini P, Ha BK, Barrett TW et al. Initial characterization and autoradiographic localization of a novel sigma/opioid binding site in immune tissues. J Neuroimmunol 1996;67:83-96.
110. 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn-Schmiedeberg's Arch Pharmacol 1999;360:209-16.
111. Wu RM, Chen RC, Chiueh CC. Effect of MAO-B inhibitors on MPP + toxicity in vivo. Ann N Y Acad Sci 2000;899:255-61.
112. Yeghiayan SK, Andersen SL, Baldessarini RJ. Lack of effect of chronic clorgyline or selegiline on dopamine and serotonin transporters in rat caudate putamen or nucleus accumbens septi. Neurosci Lett 1997;236:147-50.
113. Yu PH, Boulton AA. A comparison of the effect of brofaromine, phenelzine and tranylcypromine on the activities of some enzymes involved in the metabolism of different neurotransmitters. Res Comm Psychol Psychiatr Behav 1991;16:141-53.
114. Yu PH, Deng YL. Endogenous formaldehyde as a potential factor of vulnerability of atherosclerosis: involvement of semicarbazide-sensitive amine oxidase-mediated methylamine turnover. Atherosclerosis 1998;140:357-63.
115. Yu PH, Zuo D-M. Inhibition of a type B monoamine oxidase inhibitor, (E)-2-(4-fluorophenyl)-3-fluoroallylamine (MDL 72974A), on semicarbazide-sensitive amine oxidases isolated from vascular tissues and sera of different species. Biochem Pharmacol 1992;43:307-12.
116. Yu PH, Zuo D-M. Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia 1997;40:1243-50.
117. Zeller EA. Über den enzymatischen Abbau von Histamin und Diaminen. Helv Chim Acta 1938;21:881-90.
118. Zeller EA. The role of amine oxidases in the destruction of catecholamines. Pharmacol Rev 1959;11:387-93.